Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 8/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19166896 | 0.89 | GRIA1 (0.60) | GRIA1MAOBHTR2CHTR2AHTR2B | |
| SCHEMBL8314975 | 0.83 | GRIA1 (0.82) | GRIA1KMT2AMAPT | |
| SCHEMBL31562999 | 0.83 | GRIA1 (0.60) | GRIA1 | |
| SCHEMBL7631933 | 0.82 | GRIA1 (0.56) | GRIA1MAOBHTR2CHTR2AHTR2B | |
| SCHEMBL7631937 | 0.82 | GRIA1 (0.56) | GRIA1MAOBHTR2CHTR2AHTR2B | |
| SCHEMBL8367555 | 0.82 | GRIA1 (0.80) | GRIA1 | |
| SCHEMBL13492425 | 0.81 | GRIA1 (0.42) | GRIA1MAOBHTR2CHTR2AHTR2B | |
| SCHEMBL5806598 | 0.79 | GRIA1 (0.53) | GRIA1HTR2CHTR2AHTR2B | |
| SCHEMBL5806602 | 0.79 | GRIA1 (0.53) | GRIA1HTR2CHTR2AHTR2B | |
| SCHEMBL31563001 | 0.79 | GRIA1 (0.58) | GRIA1MAOBHTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025079090-A1 | SUBSTITUTED 4-HETEROATOM-ISOQUINOLONE COMPOUNDS, PROCESS OF PREPARATION AND APPLICATIONS THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2025-04-17 | — | — | WO | claimed |
| EP-2114158-B1 | 3-SUBSTITUTED-[1,2,3]BENZOTRIAZINONE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMA INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20080176793-A1 | UPREGULATING ACTIVITY OR EXPRESSION OF BDNF TO MITIGATE COGNITIVE IMPAIRMENT IN ASYMPTOMATIC HUNTINGTON'S SUBJECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | GRIN1, GRIN3B, GABRE | GRIA1 26/4885MAOB 418/4885HTR2C 176/4885 |
| US-20080176793-A1 | UPREGULATING ACTIVITY OR EXPRESSION OF BDNF TO MITIGATE COGNITIVE IMPAIRMENT IN ASYMPTOMATIC HUNTINGTON'S SUBJECTS | BDNF, HTT, NTRK2 | GRIA1 156/4885MAOB 1217/4885HTR2C 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.